{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:47:36Z","timestamp":1776329256518,"version":"3.50.1"},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,11]]},"DOI":"10.18632\/oncotarget.17436","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T13:59:32Z","timestamp":1493215172000},"page":"46425-46435","source":"Crossref","is-referenced-by-count":26,"title":["Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis"],"prefix":"10.18632","volume":"8","author":[{"given":"Long","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rujun","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutian","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guowei","family":"Che","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/s0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Lake","year":"2005","journal-title":"Lancet"},{"key":"2","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/jco.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Paoletti","year":"2003","journal-title":"J Clin Oncol"},{"key":"3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Pastan","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1349-7006.2007.00715.x","article-title":"Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells","volume":"99","author":"Gregoire","year":"2008","journal-title":"Cancer Sci"},{"key":"5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1200\/jco.2011.39.6671","article-title":"Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis","volume":"30","author":"Di Serio","year":"2012","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"e004145","DOI":"10.1136\/bmjopen-2013-004145","article-title":"Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis","volume":"4","author":"Shi","year":"2014","journal-title":"BMJ Open"},{"key":"7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/dma-2011-0866","article-title":"Soluble mesothelin-related peptides levels in patients with malignant mesothelioma","volume":"32","author":"Dodic-Fikfak","year":"2012","journal-title":"Dis Markers"},{"key":"8","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1158\/1078-0432.ccr-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Ambrosino","year":"2007","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/1078-0432.ccr-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Lassalle","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/1078-0432.ccr-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Nowak","year":"2011","journal-title":"Clin Cancer Res"},{"key":"11","doi-asserted-by":"publisher","first-page":"160","DOI":"10.5301\/jbm.2011.8614","article-title":"Biomarkers in malignant mesothelioma: diagnostic and prognostic role of soluble mesothelin-related peptide","volume":"26","author":"Vimercati","year":"2011","journal-title":"Int J Biol Markers"},{"key":"12","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Muley","year":"2008","journal-title":"J Thorac Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Robinson","year":"2007","journal-title":"Thorax"},{"key":"14","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/1471-2407-14-674","article-title":"A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice","volume":"14","author":"Popat","year":"2014","journal-title":"BMC Cancer"},{"key":"15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1136\/thoraxjnl-2014-205205","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","volume":"69","author":"Robinson","year":"2014","journal-title":"Thorax"},{"key":"16","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1515\/cclm.2011.242","article-title":"Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma","volume":"49","author":"Nakano","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"17","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1097\/JTO.0b013e3182272294","article-title":"Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma","volume":"6","author":"van Meerbeeck","year":"2011","journal-title":"J Thorac Oncol"},{"key":"18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor","volume":"141","author":"van Meerbeeck","year":"2012","journal-title":"Chest"},{"key":"19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/jto.0000000000000181","article-title":"Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee","volume":"9","author":"Rusch","year":"2014","journal-title":"J Thorac Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1093\/jjco\/hyq159","article-title":"Survival and prognostic factors in malignant pleural mesothelioma: a retrospective study of 314 patients in the west part of Japan","volume":"41","author":"Kishimoto","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"21","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/bjc.2014.312","article-title":"Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey","volume":"111","author":"Favaretto","year":"2014","journal-title":"Br J Cancer"},{"key":"22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1700\/1430.15816","article-title":"Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects","volume":"100","author":"Halilcolar","year":"2014","journal-title":"Tumori"},{"key":"23","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cllc.2012.03.011","article-title":"Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board","volume":"14","author":"Clarke","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2169\/internalmedicine.51.6236","article-title":"Prognostic factors in malignant pleural mesothelioma: a retrospective study","volume":"51","author":"Kawase","year":"2012","journal-title":"Intern Med"},{"key":"25","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/JTO.0b013e3181ba2033","article-title":"Prognostic factors according to the treatment schedule in malignant pleural mesothelioma","volume":"4","author":"Cadirci","year":"2009","journal-title":"J Thorac Oncol"},{"key":"26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/19338240903390271","article-title":"Prognostic factors for 100 patients with malignant pleural mesothelioma","volume":"65","author":"Gonlugur","year":"2010","journal-title":"Arch Environ Occup Health"},{"key":"27","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1177\/0218492312449633","article-title":"Prognostic factors in malignant pleural mesothelioma: role of talc pleurodesis","volume":"20","author":"McGuigan","year":"2012","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"28","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.5301\/jbm.5000229","article-title":"Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma","volume":"32","author":"Foddis","year":"2016","journal-title":"Int J Biol Markers"},{"key":"29","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment","volume":"179","author":"Scherpereel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"30","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1158\/1078-0432.ccr-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Adusumilli","year":"2012","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Ho","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"32","doi-asserted-by":"publisher","first-page":"e33214","DOI":"10.1371\/journal.pone.0033214","article-title":"Inhibition of mesothelin as a novel strategy for targeting cancer cells","volume":"7","author":"Farassati","year":"2012","journal-title":"PLoS One"},{"key":"33","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.1002\/cncr.28875","article-title":"Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125","volume":"120","author":"Pastan","year":"2014","journal-title":"Cancer"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1667","article-title":"Efficacy of anti-mesothelin immunotoxin RG7787 plus nab-paclitaxel against mesothelioma patient derived xenografts and mesothelin as a biomarker of tumor response","author":"Hassan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"35","doi-asserted-by":"publisher","first-page":"ix493","DOI":"10.1093\/annonc\/mds415","article-title":"A multi-center phase II clinical trial of the chimeric anti-mesothelin monoclonal antibody amatuximab in combination with chemotherapy for frontline therapy of malignant pleural mesothelioma: updated clinical outcomes and correlative studies","volume":"23","author":"Wallin","year":"2012","journal-title":"Ann Oncol"},{"key":"36","doi-asserted-by":"publisher","first-page":"5927","DOI":"10.1158\/1078-0432.ccr-14-0804","article-title":"Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma","volume":"20","author":"Wallin","year":"2014","journal-title":"Clin Cancer Res"},{"key":"37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00280-016-2984-z","article-title":"Population pharmacokinetics and exposure-response relationship of amatuximab, an anti-mesothelin monoclonal antibody, in patients with malignant pleural mesothelioma and its application in dose selection","volume":"77","author":"Wallin","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"38","doi-asserted-by":"publisher","first-page":"e85935","DOI":"10.1371\/journal.pone.0085935","article-title":"MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma","volume":"9","author":"Landi","year":"2014","journal-title":"PLoS One"},{"key":"39","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Altman","year":"2010","journal-title":"Int J Surg"},{"key":"40","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Sydes","year":"2007","journal-title":"Trials"},{"key":"41","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"42","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"43","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Altman","year":"2003","journal-title":"BMJ"},{"key":"44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Tweedie","year":"2000","journal-title":"Biometrics"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17436","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T20:22:57Z","timestamp":1589142177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.17436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":44,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2017,7,11]]}},"alternative-id":["17436","28507279"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.17436","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]}}}